About Alpha-1 Foundation research programs
The Alpha-1 Foundation has invested more than $50 million to support Alpha-1 Antitrypsin Deficiency research and programs at 94 institutions in North America, Europe, the Middle East, and Australia.
The overriding goal of the Foundation is to cure Alpha-1.
The specific aims of the Alpha-1 Foundation’s peer reviewed grants program are to promote research that will eventually result in the improved health of Alphas, with a focus on the lung and liver disease of Alpha-1. The program supports basic science and clinical research; the development and testing of treatments for the disease; bioethics and social research; and the promotion of education of members of the medical community regarding Alpha-1.
The Alpha-1 Project
The Alpha-1 Project (TAP) is a wholly-owned for profit subsidiary of the Alpha-1 Foundation, singularly focused on providing critical funding and advice to speed the commercialization of therapies for the elimination of Chronic Obstructive Pulmonary Disease (COPD) and liver disease caused by Alpha-1.
TAP will focus funding into highly promising drug therapies or devices in the translational research or clinical trial stage of development to speed the commercialization of these therapies. It will leverage the experience and scientific knowledge of the Alpha-1 Foundation as well as the drug therapy and device commercialization expertise of large pharmaceutical and biotechnology companies.